Ying Tang

US Patent:

7354584, Apr 8, 2008

Filed:

Apr 12, 2004

Appl. No.:

10/823253

Inventors:

Jennifer Lynne Reed - Clarksburg MD, US
Herren Wu - Boyds MD, US
Ying Tang - San Diego CA, US
Julian Davies - San Diego CA, US
Jeffry D. Watkins - Encinitas CA, US

Assignee:

MedImmune, Inc. - Gaithersburg MD

International Classification:

A61K 39/395
G01N 33/53

US Classification:

4241451, 4241331, 5303913, 5303873, 53038823

Abstract:

The present invention provides novel antibodies that immunospecifically bind to an IL-9 polypeptide and compositions comprising said antibodies. The present invention also provides methods and compositions preventing, treating, managing, and/or ameliorating diseases and disorders associated with aberrant expression and/or activity of IL 9 or IL-9 receptor or subunits thereof, autoimmune diseases, inflammatory diseases, proliferative diseases, and infections comprising administration of one or more antibodies thereof that immunospecifically bind to an IL-9 polypeptide. The invention also encompasses methods and compositions for diagnosing, monitoring, and prognosing these disorders. The present invention further relates to articles of manufacture and kits comprising antibodies that immunospecifically bind to an IL-9 polypeptide.

US Patent:

7365167, Apr 29, 2008

Filed:

Nov 26, 2001

Appl. No.:

09/995529

Inventors:

Jeffry D. Watkins - Encinitas CA, US
William D. Huse - Del Mar CA, US
Ying Tang - San Diego CA, US
Daniel Broek - Los Angeles CA, US
Peter Brooks - Carmel NY, US

Assignee:

Cell Matrix, Inc. - Carlsbad CA

International Classification:

C12P 21/08

US Classification:

5303873, 536 235, 530350, 5303871, 5303913, 5303917, 5303882

Abstract:

The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

US Patent:

7390885, Jun 24, 2008

Filed:

Dec 6, 2001

Appl. No.:

10/011250

Inventors:

Jeffry D. Watkins - Encinitas CA, US
William D. Huse - Del Mar CA, US
Ying Tang - San Diego CA, US
Daniel Broek - Los Angeles CA, US
Peter Brooks - Carmel NY, US

Assignee:

Cell Matrix, Inc. - Carlsbad CA

International Classification:

C12P 21/08

US Classification:

5303873, 536 235, 530350, 5303871, 5303913, 5303917, 5303882

Abstract:

The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

US Patent:

7566770, Jul 28, 2009

Filed:

Jul 14, 2006

Appl. No.:

11/486894

Inventors:

Jeffry D. Watkins - Encinitas CA, US
William D. Huse - Del Mar CA, US
Ying Tang - San Diego CA, US
Daniel Broek - Los Angeles CA, US
Peter Brooks - Carmel NY, US

Assignee:

Cell-Matrix, Inc. - Bethesda MD

International Classification:

C07K 16/00

US Classification:

5303871, 4241301

Abstract:

The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.

US Patent:

7575747, Aug 18, 2009

Filed:

Feb 6, 2004

Appl. No.:

10/544050

Inventors:

Julian Davies - San Diego CA, US
Ying Tang - San Diego CA, US
Jeffry Dean Watkins - Encinitas CA, US

Assignee:

Applied Molecular Evolution - San Diego CA

International Classification:

A61K 39/395
C07K 16/18

US Classification:

4241451, 53038825

Abstract:

The present invention encompasses isolated antibodies, or fragments thereof, that are humanized variants of murine antibody 266 which employ complementarity determining regions derived from murine antibody 266. The variant antibodies are useful for treatment or prevention of conditions and diseases associated with Aβ, including Alzheimer's disease, Down's syndrome, cerebral amyloid angiopathy, mild cognitive impairment, and the like.

US Patent:

7619069, Nov 17, 2009

Filed:

Oct 19, 2007

Appl. No.:

11/874952

Inventors:

Julian Davies - San Diego CA, US
Craig Duane Dickinson - San Diego CA, US
David Matthew Marquis - Encinitas CA, US
Ying Tang - San Diego CA, US
Peter Edward Vaillancourt - Del Mar CA, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K 16/00
A61K 39/395

US Classification:

5303871, 4241301

Abstract:

TGF-beta 1 binding compositions and reagents related thereto are provided. Methods of using such compositions for therapeutic purpose are also provided.

US Patent:

7740847, Jun 22, 2010

Filed:

Jul 18, 2005

Appl. No.:

11/572634

Inventors:

Barrett Allan - Encinitas CA, US
Weidong Jiang - Sunnyvale CA, US
Ying Tang - San Diego CA, US
Jeffry Dean Watkins - Encinitas CA, US

Assignee:

Applied Molecular Evolution, Inc. - San Diego CA

International Classification:

A61K 39/395
C07K 16/28
C07K 16/30
C12N 15/13
C12N 15/63
C12N 15/16

US Classification:

4241331, 4241441, 4241531, 4241551, 4241561, 4241731, 4241741, 4241431, 435 696, 4353201, 435325, 435326, 435328, 4353431, 435344, 4353441, 435358, 5303873, 53038822, 53038873, 530 388, 53038885, 536 2353

Abstract:

The present invention provides humanized anti-CD20 antibodies comprising a human IgG1 Fc region comprising an isoleucine at position 247 and a glutamine at position 339 as well as nucleic acids encoding the antibodies and methods of using the antibodies for treating lymphoma. Furthermore, the invention provides compositions comprising the antibodies and methods of producing them.

US Patent:

7763247, Jul 27, 2010

Filed:

Feb 15, 2008

Appl. No.:

12/070146

Inventors:

Jeffry D. Watkins - Encinitas CA, US
William D. Huse - Del Mar CA, US
Ying Tang - San Diego CA, US
Daniel Broek - Los Angeles CA, US
Peter Brooks - Carmel NY, US

Assignee:

Cell Matrix, Inc. - Carlsbad CA

International Classification:

A61K 39/00

US Classification:

4241331, 5303873, 5303877, 5303888, 5303913, 5303917, 4241811

Abstract:

The invention provides a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the grafted antibody or functional fragment thereof has specific binding activity for a cryptic collagen epitope. The invention also provides methods of using an antibody having specific binding activity for a cryptic collagen epitope, including methods of inhibiting angiogenesis, tumor growth, and metastasis.